Aspirin triggered lipid mediators: novel inhibitors of leucocyte trafficking

Charles N Serhan, Clary B Clish

Despite nearly 100 years of wide usage, complete knowledge of the therapeutic impact of aspirin is still evolving^{1–3} and new beneficial effects are being uncovered in cardiovascular disease and cancer.^{4–5} The irreversible acetylation of cyclo-oxygenase (COX)-1 and its more recently discovered isoform COX-2^{1–6} with inhibition of prostaglandins is well appreciated and explains some, but not all, of the pharmacological actions of aspirin.

Another series of bioactive lipid mediators on which aspirin has an impact are lipoxins (LX), and their C15 epimers (15R), denoted aspirin triggered lipoxins (ATL, fig 1), which are biosynthesised by separate routes involving transcellular circuits.⁷ Native LX in the nanomolar range inhibit the adhesion and transmigration of polymorphonuclear leucocytes (PMNs)^{8–10} and hence serve as counter-regulatory signals operative in the resolution of inflammatory sites.^{11–12} Not only do LX serve counter-regulatory roles, but specific enantiomerically modified LX (ATL) may also be actual effectors of well established anti-inflammatory therapeutic actions of aspirin. The impact of 5S,6R,15S-trihydroxy-7,9,13-*trans*-11-*cis*-eicosatetraenoic acid (LXA₄) and ATL was investigated in tumour necrosis factor (TNFα) initiated PMN responses in vitro and in vivo using the metabolically more stable LX analogues 15R/S-methyl-LXA₄ and 15-epi-16-(parafluoro)-phenoxy-LXA₄. These compounds represent subtle modifications to the native LXA₄ and ATL structure that prevent rapid metabolic inactivation of the lipoxin and 15-epi-LX structures.^{13–14} These compounds are also potent novel inhibitors of TNFα driven PMN associated inflammatory events in vitro as well as in vivo, as shown in a murine model with end points relevant to pulmonary inflammation.

Center for
Experimental
Therapeutics and
Reperfusion Injury,
Department of
Anesthesiology,
Perioperative and Pain
Medicine, Brigham
and Women's Hospital,
Harvard Medical
School, Boston,
Massachusetts 02115,
USA
C N Serhan
C B Clish

Correspondence to:
Dr C N Serhan
cnserrhan@
zeus.bwh.harvard.edu

Figure 1 Generation of aspirin triggered lipid mediators (ATLM): anti-inflammation signals. Arachidonic acid can be transformed via COX-1 or its inducible isoform COX-2 to produce prostaglandins and thromboxane. Acetylation by aspirin blocks this conversion.^{1–6} The lipoxins (LX) are biosynthesised through transcellular interactions and production of 15-epi-LX is triggered when COX-2 is acetylated by aspirin. LX and aspirin triggered lipoxins (ATL) have potent inhibitory actions since their longer acting stable analogues are potent in vivo^{8–13–14} and appear to be involved in healing/resolution and anti-inflammation.

Methods

Six day air pouches were raised on the dorsum of 6–8 week old male BALB/c mice by subcutaneous injection of 3 ml sterile air and experiments were conducted on day 6.^{13–15} Individual air pouches were injected with either vehicle alone (0.1% ethanol), TNFα, ATL stable analogue, or TNFα + ATL, with each suspended in 1 ml of endotoxin free phosphate buffered saline (PBS; pH 7.45) immediately before injection into pouch cavities. Mice were sacrificed and individual air pouches were lavaged, and the cell exudates were measured and analysed for cytokines/chemokines.¹³

Results

PMNs express and release several cytokines among which interleukin (IL)-1β is a potent proinflammatory agent.¹⁶ We have recently investigated the actions of native LXA₄ and its stable analogues on TNFα induced IL-1β release.¹³ PMNs from healthy donors were exposed to increasing concentrations of 15R/S-methyl-LXA₄ or native LXA₄ in the presence of TNFα (25 000–50 000 activity units/ml) or vehicle alone. At a concentration of 100 nM, 15R/S-methyl-LXA₄ inhibited approximately 60% of IL-1β release, a value which is comparable to that obtained with native LXA₄. Inhibition of IL-1β by LXA₄ and its stable analogue was, at least in part, the result of a down-regulation in gene expression, since the IL-1β messenger RNA levels in cells treated with TNFα (10 ng/ml) plus 15R/S-methyl-LXA₄ (100 nM) were decreased by approximately 60% compared with cells treated with TNFα alone.¹³ Since IL-1β and TNFα are two cytokines considered to be important in inflammation, the inhibition of IL-1β suggested that ATL might exert an in vivo anti-cytokine action.

TNFα evokes leucocyte infiltration in a chemokine-dependent fashion in the murine six day air pouch.¹⁵ We therefore evaluated the impact of ATL stable analogues 15R/S-methyl-LXA₄ and 15-epi-16-(para-fluoro)-phenoxy-LXA₄ in this model to determine whether they also intersect the cytokine/chemokine axis in vivo and inhibit leucocyte infiltration.^{13–14} Murine TNFα gives a transient infiltration of leucocytes to the pouch cavity in a time-dependent fashion with maximal accumulation at four hours.¹³ 15R/S-methyl-LXA₄ at a concentration of 25 nmol inhibited the TNFα stimulated recruitment of leucocytes by approximately 62%. Inhibition was evident at one hour and was maximal at 2–4 hours. At these intervals a reduction in leucocyte infiltration of more than 60% was noted that remained significantly reduced at eight hours. Inflamma-

Figure 2 15R/S-methyl-LXA₄ redirects the TNF α induced cytokine/chemokine profile in vivo. Sterile PBS (~1 ml) containing either 0.1% ethanol, TNF α , 15R/S-methyl-LXA₄, or TNF α + 15R/S-methyl-LXA₄ was injected into the pouches and individual lavage exudates were collected at the indicated time periods. Measurements were performed with air pouch cell-free lavage exudates as described by Hachicha *et al.*¹³ The results are expressed as the % change compared with the quantities of cytokines found in TNF α injected air pouches in the absence of LXA₄ (mean (SE) from three different mice for each time interval). Changes in IL-1 β , MIP-2, and IL-4 secretion were statistically significant at all tested time intervals ($p < 0.01$). At one hour the air pouches injected with TNF α alone generated 384 (12) pg MIP-2/pouch and 14.9 (2.3) pg IL-1 β /pouch. 15R/S-methyl-LXA₄ alone generated 42.7 (0.7) pg IL-4/pouch.

tory exudates were collected four hours after injections and trafficking of cell types into the cavity was measured. In the six day pouches given TNF α , PMNs constituted the major cell type present within the exudates at four hours with a range of 80–85%. Administration of both 15R/S-methyl-LXA₄ and TNF α into the six day air pouch cavity inhibited migration of PMNs, eosinophils, and basophils as well as mononuclear cells.¹³ The fluorinated ATL analogue was compared with aspirin in this model and, when injected into the pouch with TNF α , more than 75% inhibition was achieved with 10 μ g. This analogue also showed increased stability in whole blood (mouse and human) and intravenous administration was as effective as administration into the air pouch (topical). This stable ATL analogue was also about 100 times more potent than aspirin in blocking PMN influx to the pouch.¹⁴

Since macrophage inflammatory peptide (MIP)-2 is the major chemokine involved in recruiting PMNs to the pouch cavity following injection of TNF α ,¹⁵ we determined the action of 15R/S-methyl-LXA₄ in this TNF α induced chemokine-cytokine axis. MIP-2 and IL-1 β are important proinflammatory cytokines, and IL-4, IL-10, and IL-13 possess immunomodulatory properties. Exudates from selected time intervals were collected and cell-free supernatants assessed for the presence of these murine cytokines. 15R/S-methyl-LXA₄ (25 nmol)

inhibited TNF α stimulated MIP-2 and IL-1 β release by 48% and 30%, respectively (fig 2). 15R/S-methyl-LXA₄ alone in the air pouch did not stimulate MIP-2 or IL-1 β release. In sharp contrast, 15R/S-methyl-LXA₄ stimulated the appearance of IL-4 within the exudates. This stimulation of IL-4 was observed both with and without TNF α . Neither IL-10 nor IL-13 was detected within the pouch exudates. These results show that administration of 15R/S-methyl-LXA₄ dramatically modified the cytokine/chemokine axis in TNF α initiated acute inflammation and, interestingly, this re-orientation of the cytokine/chemokine axis paralleled the reduction in leucocyte infiltration.

Discussion

LXA₄ and ATL (generated by separate biosynthetic mechanisms in vivo; fig 1 and Serhan *et al.*^{10–12}), as evidenced by the actions of the metabolically stable analogue 15R/S-methyl-LXA₄, are both potent cytokine regulating lipid mediators that can also have an impact on the course of inflammation initiated by TNF α . In this exudate and skin wound model,¹³ 15R/S-methyl-LXA₄ not only inhibited TNF α elicited PMNs, monocytes, basophils, and eosinophils as well as the appearance of IL-1 β and MIP-2, but also stimulated IL-4 appearance within the pouch. These results provide the first evidence to indicate that lipoxins and ATL induce upregulation of potential “anti-inflammatory” cytokines such as IL-4.¹⁷ It is likely that both the inhibition of IL-1 β and MIP-2 within exudates and IL-4 levels in the surrounding tissues by metabolically stable LX analogues may represent, in part, some of the in vivo impact of LXA₄ and aspirin triggered 15-epi-LXA₄. These findings provide a new understanding of the relationship between “anti-inflammatory” cytokines and lipid mediators and also open new avenues to investigate protective lipid and protein mediators in host defence.

In summary, these results suggest that LXA₄ and aspirin triggered LXA₄ appear to be involved in controlling not only acute inflammatory responses, but also mechanisms that can influence chronic inflammatory responses. The recent results reviewed here also support the notion that aspirin may exert its beneficial action in part via the biosynthesis of endogenous ATLMs such as 15-epi-LXA₄ that can, in turn, act directly on PMNs as well as affect the appearance of chemokines and cytokines. Thus, LX-ATL can protect host tissues via multi-level regulation of proinflammatory signals and may be relevant new lipid mediators of interest in airway diseases.

These studies were supported in part by National Institutes of Health grant no. GM-38765. CC is an Arthritis Foundation postdoctoral fellow.

- 1 Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol* 1998;38:97–120.
- 2 Marcus AJ. Aspirin as prophylaxis against colorectal cancer. *N Engl J Med* 1995;333:656–8.
- 3 Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NF κ B. *Proc Natl Acad Sci USA* 1999;96:6377–81.

- 4 Ridker PM, Cushman M, Stampfer MJ, *et al.* Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997;336:973–9.
- 5 Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. *FASEB J* 1997;11:234–7.
- 6 Herschman HR. Recent progress in the cellular and molecular biology of prostaglandin synthesis. *Trends Cardiovasc Med* 1998;8:145–50.
- 7 Serhan CN, Haeggström JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. *FASEB J* 1996;10:1147–58.
- 8 Takano T, Fiore S, Maddox JF, *et al.* Aspirin-triggered 15-epi-lipoxin A₄ and LXA₄ stable analogs are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. *J Exp Med* 1997;185:1693–704.
- 9 Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. *Proc Natl Acad Sci USA* 1995;92:9475–9.
- 10 Colgan SP, Serhan CN, Parkos CA, *et al.* Lipoxin A₄ modulates transmigration of human neutrophils across intestinal epithelial monolayers. *J Clin Invest* 1993;92:75–82.
- 11 Serhan CN, Takano T, Gronert K, *et al.* Lipoxin and aspirin-triggered 15-epi-lipoxin cellular interactions: anti-inflammatory lipid mediators. *Clin Chem Lab Med* 1999;37:299–309.
- 12 Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins. In: Gallin JI, Snyderman R, eds. *Inflammation: basic principles and clinical correlates*. Philadelphia: Lippincott Williams & Wilkins, 1999: 373–85.
- 13 Hachicha M, Pouliot M, Petasis NA, *et al.* Lipoxin (LX)A₄ and aspirin-triggered 15-epi-LXA₄ inhibit tumor necrosis factor 1 α -initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. *J Exp Med* 1999;189:1923–9.
- 14 Clish CB, O'Brien JA, Gronert K, *et al.* Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. *Proc Natl Acad Sci USA* 1999;96:8247–52.
- 15 Tessier PA, Naccache PH, Clark-Lewis I, *et al.* Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF- α . *J Immunol* 1997;159:3595–602.
- 16 Marucha PT, Zeff RA, Kreutzer DL. Cytokine-induced IL-1 β gene expression in the human polymorphonuclear leukocyte: transcriptional and post-transcriptional regulation by tumor necrosis factor and IL-1. *J Immunol* 1991;147:2603–8.
- 17 Lehn M, Weiser WY, Engelhorn S, *et al.* IL-4 inhibits H₂O₂ production and antileishmanial capacity of human cultured monocytes mediated by IFN- γ . *J Immunol* 1989;143:3020–4.